Anti-Bevacizumab Antibody (11C1), mAb, Mouse
Anti-Bevacizumab Antibody (11C1), MAb, Mouse

Figure 1. ELISA binding of Anti-Bevacizumab Antibody (11C1), mAb, Mouse (GenScript, A02185) with Bevacizumab. While the antibody does not recognize the human IgG (data not shown).

Coating antigen: Bevacizumab, 1 µg/ml.

Anti-Bevacizumab Antibody (11C1), mAb, Mouse (GenScript, A02185) dilution start from 1,000 ng/ml.

Anti-Bevacizumab Antibody (11C1), MAb, Mouse

Figure 2. Standard curve of Bevacizumab Sandwich CLIA (Chemiluminescent immunoassay).

The Bevacizumab Sandwich CLIA assay is developed by using Anti-Bevacizumab Antibody (11C1), mAb, Mouse (GenScript, A02185) and MonoRab™ Anti-Bevacizumab Antibody (46E3)[Biotin], mAb, Rabbit (GenScript, A01896) as the capture and detection antibodies, respectively.

Capture antibody: Anti-Bevacizumab Antibody (11C1), mAb, Mouse, 1.5 μg/ml

Detection antibody: MonoRab™ Anti-Bevacizumab Antibody (46E3)[Biotin], mAb, Rabbit, 0.5 μg/ml

Anti-Bevacizumab Antibody (11C1), mAb, Mouse

The product is specific for Bevacizumab. The antibody is recommended as a capture antibody in a pharmacokinetic (PK) bridging assay with detection antibody MonoRab™ Anti-Bevacizumab Antibody (46E3), mAb, Rabbit (GenScript, A01962) or MonoRab™ Anti-Bevacizumab Antibody (46E3)[Biotin], mAb, Rabbit (GenScript, A01896) .
A02185
¥25,548.00

Ask us a question
Overview
Specificity The product is specific for Bevacizumab. The antibody is recommended as a capture antibody in a pharmacokinetic (PK) bridging assay with detection antibody GenScript A01962 or A01896, MonoRab™ Anti-Bevacizumab Antibody (46E3), mAb, Rabbit.
Host Species Mouse
Immunogen Bevacizumab
Conjugate Unconjugated

Applications
Working concentrations for specific applications should be determined by the investigators. The appropriate concentrations may be affected by secondary antibody affinity, antigen concentration, the sensitivity of the method of detection, temperature, the length of the incubations, and other factors. The suitability of this antibody for applications other than those listed below has not been determined. The following concentration ranges are recommended starting points for this product.
Application Recommended Usage
ELISA 0.01-0.1 µg/ml
Chemiluminescent immunoassay (CLIA) 0.5-2 µg/ml

Properties
Form Lyophilized
Storage Buffer Lyophilized with PBS, pH 7.2, containing 0.02% sodium azide.
Reconstitution Reconstitute the lyophilized powder with deionized water (or equivalent) to an final concentration of 0.5 mg/mL.
Storage Instructions The lyophilized product remains stable up to 1 year at -20 °C from date of receipt. Upon reconstitution, it can be stored for 2-3 weeks at 2-8 °C or for up to 12 months at -20 °C or below. Avoid freeze/thaw cycles.
Purification Protein A affinity column
Isotype Mouse IgG1, κ
Clonality Monoclonal
Clone ID 11C1
Note GenScript can customize this product per customer's request including product size, buffer components, etc.

Examples
  • Anti-Bevacizumab Antibody (11C1), MAb, Mouse
    • Anti-Bevacizumab Antibody (11C1), MAb, Mouse

    Figure 1. ELISA binding of Anti-Bevacizumab Antibody (11C1), mAb, Mouse (GenScript, A02185) with Bevacizumab. While the antibody does not recognize the human IgG (data not shown).

    Coating antigen: Bevacizumab, 1 µg/ml.

    Anti-Bevacizumab Antibody (11C1), mAb, Mouse (GenScript, A02185) dilution start from 1,000 ng/ml.

  • Anti-Bevacizumab Antibody (11C1), MAb, Mouse
    • Anti-Bevacizumab Antibody (11C1), MAb, Mouse

    Figure 2. Standard curve of Bevacizumab Sandwich CLIA (Chemiluminescent immunoassay).

    The Bevacizumab Sandwich CLIA assay is developed by using Anti-Bevacizumab Antibody (11C1), mAb, Mouse (GenScript, A02185) and MonoRab™ Anti-Bevacizumab Antibody (46E3)[Biotin], mAb, Rabbit (GenScript, A01896) as the capture and detection antibodies, respectively.

    Capture antibody: Anti-Bevacizumab Antibody (11C1), mAb, Mouse, 1.5 μg/ml

    Detection antibody: MonoRab™ Anti-Bevacizumab Antibody (46E3)[Biotin], mAb, Rabbit, 0.5 μg/ml


Background
Target Background Bevacizumab (Avastin) is a humanized monoclonal antibody that is approved by the U.S. Food and Drug Administration for the treatment of a number of types of cancers and a specific eye disease. Bevacizumab binds to a continuous epitope in VEGF, preventing interaction of VEGF with VEGFR on the surface of endothelial cells. It can be used to inhibit solid tumours growth and metastasis by weakening tumour angiogenesis.
Synonyms Avastin

For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.